Remove Anatomy Remove Innovation Remove TAVR
article thumbnail

Medtronic Announces FDA Approval of Newest-generation Evolut TAVR System for Treatment of Symptomatic Severe Aortic Stenosis

DAIC

milla1cf Thu, 03/28/2024 - 07:30 March 28, 2024 — Medtronic plc, a global leader in healthcare technology, announced that the United States Food and Drug Administration ( FDA ) has approved the Evolut FX+ transcatheter aortic valve replacement (TAVR) system for the treatment of symptomatic severe aortic stenosis.

TAVR 111
article thumbnail

New Data for Medtronic CoreValve/Evolut TAVR Systems Reinforces Excellent Valve Performance

DAIC

milla1cf Fri, 06/07/2024 - 14:50 June 7, 2024 — Medtronic today announced new data from the CoreValve Evolut Clinical Program , reinforcing the positive performance of the Evolut transcatheter aortic valve replacement (TAVR) System compared to surgical aortic valve replacement (SAVR) and other TAVR valves. Evolut vs. 10.6%

TAVR 111
article thumbnail

American College of Cardiology (ACC24) Show Preview: Advancing Cardiovascular Care for All

DAIC

We hope that the anniversary contributions will help to support the college's mission and mission-focused work that empowers future leaders in the next generation of cardiovascular innovators through scholarship, mentorship and leadership development programs. “We Session 510) To Treat or Not to Treat Anatomy and Ischemia?

article thumbnail

SPONSORED CONTENT: Unveiling the Future of Cardiovascular Workflow

DAIC

To this end, ASCEND provides the tools that not only address the unique needs of each cardiovascular subspecialty and to care for patients from infancy into their golden years, they also innovates next-generation solutions and services that empower the provider community to truly transform their cardiovascular services.